lapatinib has been researched along with ag 1879 in 5 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (ag 1879) | Trials (ag 1879) | Recent Studies (post-2010) (ag 1879) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 575 | 0 | 215 |
| Protein | Taxonomy | lapatinib (IC50) | ag 1879 (IC50) |
|---|---|---|---|
| Chain A, Lck Kinase | Homo sapiens (human) | 0.02 | |
| Chain A, Tyrosine-protein kinase Lyn | Mus musculus (house mouse) | 0.009 | |
| Chain A, Tyrosine-protein kinase Lyn | Mus musculus (house mouse) | 0.009 | |
| Receptor-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | 0.019 | |
| Proto-oncogene tyrosine-protein kinase Src | Gallus gallus (chicken) | 0.036 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.48 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.004 | |
| Proto-oncogene tyrosine-protein kinase LCK | Mus musculus (house mouse) | 0.031 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 0.0052 | |
| Tyrosine-protein kinase Lyn | Homo sapiens (human) | 0.0005 | |
| Tyrosine-protein kinase HCK | Homo sapiens (human) | 0.005 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 1.1814 | |
| Tyrosine-protein kinase CSK | Homo sapiens (human) | 0.5 | |
| Casein kinase I isoform delta | Homo sapiens (human) | 0.041 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 4.23 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
| Debnath, B; Ding, J; Kazemi, R; Long, YQ; Neamati, N; Odde, S; Sanchez, TW; Wang, Y; Xie, H; Xu, S; Xu, ZL; Yang, LM; Zeng, LF; Zheng, YT | 1 |
| Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR | 1 |
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
| Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR | 1 |
5 other study(ies) available for lapatinib and ag 1879
| Article | Year |
|---|---|
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties.
Topics: Antineoplastic Agents; Drug Design; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Models, Molecular; Molecular Structure; Naphthyridines; Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured; Virus Integration | 2012 |
Highly predictive and interpretable models for PAMPA permeability.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine | 2017 |
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States | 2020 |